http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
PolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results
-
PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference
-
PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024
-
PolyPid Ltd. (PYPD) Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal C
-
PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Su
-
PolyPid (PYPD) Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Inf
-
PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Inf
-
PolyPid to Participate in Three Upcoming Fall Investor Conferences
-
PolyPid Provides Corporate Update and Reports Second Quarter 2024 Financial Results
-
PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds
-
PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024
-
PolyPid Hosts KOL Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides Update on its Ongoing SHIELD II Phase 3 Trial
-
PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company’s Ongoing D-PLEX₁₀₀ Phase 3 Trial
-
PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results
-
PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results
-
PolyPid to Participate in Citizens JMP Life Sciences Conference
-
PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
-
PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024
-
PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference
-
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-
PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial
-
PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial
-
PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024
-
PolyPid Ltd. (PYPD) Announces $16.2M Private Placement at $4.81/sh
-
PolyPid Announces Private Placement for $16 Million in Gross Proceeds
-
PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results
-
PolyPid Ltd. (PYPD) Appoints Nurit Tweezer-Zaks to its Board
-
PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors
-
PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023
-
PolyPid Ltd. (PYPD) Regains Nasdaq Compliance
-
PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
-
PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023
-
PolyPid Ltd. (PYPD) Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX and PLEX Technology Platform
-
PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology Platform
-
PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
-
PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health
-
PolyPid Ltd. (PYPD) Announces 1:30 Reverse Share Split
-
PolyPid Announces Reverse Share Split
-
PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX₁₀₀
-
PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial Results
-
PolyPid to Report Second Quarter 2023 Financial Results and Operational Highlights on August 9, 2023
-
PolyPid Announces New Publication Highlighting Potent Antibacterial Activity of D-PLEX₁₀₀ against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections
-
PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections
-
PolyPid Ltd. (PYPD) Granted 180-Day Extension to Regain Nasdaq Compliance
-
PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital Market
-
PolyPid Ltd. (PYPD) Announces FDA Agreement of Design of SHIELD II Phase 3 Trial
-
PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections
-
PolyPid Provides Corporate Update and Reports First Quarter 2023 Financial Results
-
PolyPid to Report First Quarter 2023 Financial Results and Operational Highlights on May 10, 2023
-
PolyPid to Participate in Upcoming Investor Conferences
